Karuna's schizophrenia drug meets main goal in late-stage trial (updated)

Karuna Therapeutics

20/03/2023 10:42

(Adds details on data)
    By Leroy  Leo
       March 20 (Reuters) - Karuna Therapeutics  KRTX.O  said
on Monday its experimental drug significantly reduced symptoms
of schizophrenia in a late-stage trial.
    The drug KarXT met its primary goal by showing a
statistically significant and clinically meaningful 8.4-point
reduction in a medical scale used to measure the severity of
schizophrenia symptoms.
    Karuna Therapeutics said it missed one of its secondary
goals for improvement in symptoms like hallucinations and
delusions, but showed a significant decline in two other
secondary goals.
    The latest data supports results from earlier trials of the
drug and will form part of the application to the U.S. Food and
Drug Administration, which the company expects in mid-2023.
    The company is targeting a potential launch for the drug in
the second half of next year.
    The company in November 2021 partnered with Zai Lab Ltd
 9688.HK  for development, manufacturing, and commercialization
of KarXT in Greater China.

 (Reporting by Leroy Leo in Bengaluru; Editing by Sriraj
Kalluvila)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))